CELU Stock Forecast: Celularity, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.46
−1.88% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$15.0M
Ticker Nerd rank
29/ 100
Median analyst target
—
Analysts covering
—
Revenue$4.1M−77.4% y/y
Operating income−$22.1M
Net income−$24.4M
Free cash flow−$5.1M
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Total return, dividends reinvested
1W
−27.1%
1M
−63.6%
YTD
−58.6%
1Y
−73.2%
From 52W high
−78.1%
From 52W low
0.0%
$0.46
$2.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Celularity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Growth
47
Momentum
39
Issuance
39
Quality
28
Revisions
20
Value
18
Volatility
10

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CELU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26CELU

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 13 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
9 Sept 2025WBB SecuritiesUpgradeBuy$6.00
18 Aug 2025WBB SecuritiesInitiatesSpeculative Buy—
30 Jan 2023HC Wainwright & Co.MaintainsBuy$15 → $2.50
30 Jan 2023Morgan StanleyDowngradeUnderweight$5.00 → $1.00
22 Dec 2022OppenheimerDowngradePerform—
12 Sept 2022Morgan StanleyMaintainsEqual-Weight$8.00 → $5.00
25 Aug 2022Alliance Global PartnersInitiatesBuy$15
23 Aug 2022Truist SecuritiesMaintainsHold$10 → $6.00
22 June 2022HC Wainwright & Co.InitiatesBuy—
6 Apr 2022Truist SecuritiesDowngradeHold—
28 Jan 2022OppenheimerInitiatesOutperform—
24 Nov 2021Morgan StanleyInitiatesEqual-Weight—
19 Oct 2021Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CELU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CELU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Celularity, Inc. returned −73.2% against +6.9% for the S&P 500, dividends included.

CELU vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CELUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.8×

Cheaper than 70% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
−79.7%

Higher than 2% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−27.4%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celularity, Inc. has a market value of $15.0M and an enterprise value of $86.2M.

  • Revenue in the twelve months to 31 Dec 2025: $26.6M. The latest quarter shrank 77.4% year on year.

  • Net income over the same four quarters: −$91.7M, a −345.4% net margin.

  • Free cash flow in the twelve months to 31 Dec 2025: −$13.3M, after $0.0 of capital spending.

  • Shares outstanding: 28.8M.

  • Celularity, Inc. employs 115 people — $231K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CELU and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELUCelularity, Inc.$15.0M29
CNTXContext Therapeutics, Inc.$14.7M38
PBMPsyence Biomedical Ltd.$15.8M4
ATOSAtossa Therapeutics, Inc.$15.9M22
CTXRCitius Pharmaceuticals, Inc.$14.0M34
LPCNLipocine, Inc.$16.4M39
BYSIBeyondSpring, Inc.$13.7M11

Take a look at CELU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Celularity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CELU

How does Ticker Nerd's model rank CELU?

As at 21 Nov 2026, Celularity, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

What is the CELU stock forecast for 2030?

No analyst covering Celularity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELU are extrapolating price history, which says nothing about the business.

How has CELU stock performed over the past year?

Celularity, Inc. returned -73.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celularity, Inc. do?

Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking.

Company

About Celularity, Inc.

Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The Cell Therapy segment develops off-the-shelf, cryopreserved allogeneic cell therapies, including programs based on mesenchymal-like adherent stromal cells, natural killer cells, and engineered T-cells for oncology, immune, infectious, and age-related diseases. The Degenerative Disease segment supports products used in surgical and wound care markets, while BioBanking provides storage services for stem cells from umbilical cords and placentas. Headquartered in Florham Park, New Jersey, Celularity occupies a niche within biotechnology that combines regenerative medicine research with commercial biobanking and biomaterials services.

CEO Dr. Robert Joseph Hariri M.D., Ph.D. · 115 employees · United States · https://www.celularity.com